Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02255461 · OUTCOME

Association Between Lymphopenia and Single Dose Palbociclib AUC

Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors · Source last updated 2021-03-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
h*ng/mL
Interval / dispersion
Standard Deviation
Time frame
Up to approximately 4 weeks

What was measured

Lymphocyte count decreased adverse events observed in course 1 that were at least possibly attributable to palbociclib were included in analysis. Based on the highest toxicity grade reported, all participants, irrespective of their dose level or stratum, were combined and classified into three categories: 0 = no toxicity reported, 1 = grade 1 or 2, and 2 = grade 3 or 4. Association between Lymphocyte count decreased and single dose palbociclib AUC for all participants was examined.

Analysis population: It was pre-specified that data from all participants from different dose levels and strata were combined to calculate an association between lymphopenia and single dose AUC for all participants. Of 35 patients enrolled, one patient in stratum II withdrew prior to protocol therapy and was excluded.

Groups in this outcome

All Patients

All 34 patients who had course 1 single dose palbociclib AUC data available were included in analysis. Patients were classified into no lymphopenia (n = 17), grade 1 or 2 lymphopenia (n = 10), and grade 3 or 4 lymphopenia (n = 7).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
All Patients34

Reported measurements

No lymphopenia

Analysis denominator · Participants

GroupSource count
All Patients17
Values in h*ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
All Patients1727.5882.6Not reportedNot reportedNot reported
Grade 1 or 2 lymphopenia

Analysis denominator · Participants

GroupSource count
All Patients10
Values in h*ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
All Patients1837.9592.7Not reportedNot reportedNot reported
Grade 3 or 4 lymphopenia

Analysis denominator · Participants

GroupSource count
All Patients7
Values in h*ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
All Patients2159.0793.7Not reportedNot reportedNot reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    0.97
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    1.15
    group Ids
    1. OG000
    non Inferiority Comment
    Ordinal logistic regression model was built for outcome lymphopenia (0/1/2). Explanatory variable AUC was transformed by dividing by 100.
    non Inferiority Type
    OTHER
    param Type
    Odds Ratio (OR)
    param Value
    1.05
Complete source fields
analyses
  1. ci Lower Limit
    0.97
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    1.15
    group Ids
    1. OG000
    non Inferiority Comment
    Ordinal logistic regression model was built for outcome lymphopenia (0/1/2). Explanatory variable AUC was transformed by dividing by 100.
    non Inferiority Type
    OTHER
    param Type
    Odds Ratio (OR)
    param Value
    1.05
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        882.6
        value
        1727.5
    denoms
    1. counts
      1. group Id
        OG000
        value
        17
      units
      Participants
    title
    No lymphopenia
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        592.7
        value
        1837.9
    denoms
    1. counts
      1. group Id
        OG000
        value
        10
      units
      Participants
    title
    Grade 1 or 2 lymphopenia
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        793.7
        value
        2159.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        7
      units
      Participants
    title
    Grade 3 or 4 lymphopenia
denoms
  1. counts
    1. group Id
      OG000
      value
      34
    units
    Participants
description
Lymphocyte count decreased adverse events observed in course 1 that were at least possibly attributable to palbociclib were included in analysis. Based on the highest toxicity grade reported, all participants, irrespective of their dose level or stratum, were combined and classified into three categories: 0 = no toxicity reported, 1 = grade 1 or 2, and 2 = grade 3 or 4. Association between Lymphocyte count decreased and single dose palbociclib AUC for all participants was examined.
dispersion Type
Standard Deviation
groups
  1. description
    All 34 patients who had course 1 single dose palbociclib AUC data available were included in analysis. Patients were classified into no lymphopenia (n = 17), grade 1 or 2 lymphopenia (n = 10), and grade 3 or 4 lymphopenia (n = 7).
    id
    OG000
    title
    All Patients
param Type
MEAN
population Description
It was pre-specified that data from all participants from different dose levels and strata were combined to calculate an association between lymphopenia and single dose AUC for all participants. Of 35 patients enrolled, one patient in stratum II withdrew prior to protocol therapy and was excluded.
reporting Status
POSTED
time Frame
Up to approximately 4 weeks
title
Association Between Lymphopenia and Single Dose Palbociclib AUC
type
SECONDARY
unit Of Measure
h*ng/mL

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice